Immatics announces $125 million underwritten offering

▤ Summary

German cancer specialist Immatics (Nasdaq: IMTX) announced today that it has agreed to sell 12,500,000 ordinary shares at $10.00 per share in an underwritten offering, with the news sending the firms shares up 13.5% to $10.26.The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be $125 million. The offering is expected to close on December 8, 2025, subject to customary closing conditions.Jefferies, Leerink Partners and Cantor Fitzgerald are acting as joint book-running managers for the offering.

▦ Linked Companies